Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Overview
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Companies Involved in Therapeutics Development
Affitech A/S
ChemoCentryx Inc
CohBar Inc
Eight Plus One Pharmaceutical Co Ltd
Lassogen Inc
RAPT Therapeutics Inc
Tizo Therapeutics Inc
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Drug Profiles
AT-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BJY-809 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-6239 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FLX-475 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Target CD30 and CCR4 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAS-20X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Target CCR4 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Inhibit CXCR4 for Melanoma and Orphan Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RPT-193 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Dormant Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Discontinued Products
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Top 10 Indications, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020


List of Tables


Number of Products under Development by Stage of Development, H2 2020
Number of Products under Development by Therapy Areas, H2 2020
Number of Products under Development by Indications, H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Products under Development by Companies, H2 2020 (Contd..2), H2 2020
Products under Development by Companies, H2 2020 (Contd..3), H2 2020
Number of Products under Investigation by Universities/Institutes, H2 2020
Products under Investigation by Universities/Institutes, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Pipeline by Actavalon Inc, H2 2020
Pipeline by Active Biotech AB, H2 2020
Pipeline by Ampio Pharmaceuticals Inc, H2 2020
Pipeline by AnTolRx Inc, H2 2020
Pipeline by Bayer AG, H2 2020
Pipeline by Dermavant Sciences Inc, H2 2020
Pipeline by Hercules Pharmaceuticals BV, H2 2020
Pipeline by Hutchison MediPharma Ltd, H2 2020
Pipeline by Ikena Oncology Inc, H2 2020
Pipeline by JAGUAHR Therapeutics Pte Ltd, H2 2020
Pipeline by Magenta Therapeutics Inc, H2 2020
Pipeline by Pfizer Inc, H2 2020
Pipeline by Phenex Pharmaceuticals AG, H2 2020
Pipeline by Shenogen Pharma?Group Ltd, H2 2020
Pipeline by Sol-Gel Technologies Ltd, H2 2020
Pipeline by Welichem Biotech Inc, H2 2020
Dormant Products, H2 2020
Dormant Products, H2 2020 (Contd..1), H2 2020
Discontinued Products, H2 2020